Literature DB >> 10945804

What contributes to quality of life in patients with Parkinson's disease?

A Schrag1, M Jahanshahi, N Quinn.   

Abstract

OBJECTIVE: To identify the factors that determine quality of life (QoL) in patients with idiopathic Parkinson's disease in a population based sample. Quality of life (QoL) is increasingly recognised as a critical measure in health care as it incorporates the patients' own perspective of their health.
METHODS: All patients with Parkinson's disease seen in a population based study on the prevalence of parkinsonism were asked to complete a disease-specific QoL questionnaire (PDQ-39) and the Beck depression inventory. A structured questionnaire interview and a complete neurological examination, including the Hoehn and Yahr scale, the Schwab and England disability scale, the motor part of the unified Parkinson's disease rating scale (UPDRS part III), and the mini mental state examination were performed by a neurologist on the same day.
RESULTS: The response rate was 78%. The factor most closely associated with QoL was the presence of depression, but disability, as measured by the Schwab and England scale, postural instability, and cognitive impairment additionally contributed to poor QoL. Although the UPDRS part III correlated significantly with QoL scores, it did not contribute substantially to predicting their variance once depression, disability, and postural instability had been taken into account. In addition, patients with akinetic rigid Parkinson's disease had worse QoL scores than those with tremor dominant disease, mainly due to impairment of axial features.
CONCLUSION: Depression, disability, postural instability, and cognitive impairment have the greatest influence on QoL in Parkinson's disease. The improvement of these features should therefore become an important target in the treatment of the disease.

Entities:  

Mesh:

Year:  2000        PMID: 10945804      PMCID: PMC1737100          DOI: 10.1136/jnnp.69.3.308

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  23 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

3.  Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group.

Authors:  J Jankovic; M McDermott; J Carter; S Gauthier; C Goetz; L Golbe; S Huber; W Koller; C Olanow; I Shoulson
Journal:  Neurology       Date:  1990-10       Impact factor: 9.910

4.  Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study.

Authors:  A Schrag; Y Ben-Shlomo; N P Quinn
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Measuring quality of life in a way that is meaningful to stroke patients.

Authors:  L S Williams; M Weinberger; L E Harris; J Biller
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

Review 7.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

8.  Depression in torticollis: a controlled study.

Authors:  M Jahanshahi; C D Marsden
Journal:  Psychol Med       Date:  1988-11       Impact factor: 7.723

9.  The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

Authors:  C A McHorney; J E Ware; A E Raczek
Journal:  Med Care       Date:  1993-03       Impact factor: 2.983

10.  The heterogeneity of Parkinson's disease: clinical and prognostic implications.

Authors:  W J Zetusky; J Jankovic; F J Pirozzolo
Journal:  Neurology       Date:  1985-04       Impact factor: 9.910

View more
  309 in total

1.  Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments.

Authors:  J Marinus; C Ramaker; J J van Hilten; A M Stiggelbout
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 2.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 3.  Measurement of quality of life in neurodegenerative disorders.

Authors:  M D Welsh
Journal:  Curr Neurol Neurosci Rep       Date:  2001-07       Impact factor: 5.081

Review 4.  Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.

Authors:  Judith Dams; Bernhard Bornschein; Jens Peter Reese; Annette Conrads-Frank; Wolfgang H Oertel; Uwe Siebert; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

5.  The relative health related quality of life of veterans with Parkinson's disease.

Authors:  H Gage; A Hendricks; S Zhang; L Kazis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

Review 6.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

7.  Axial rigidity and quality of life in patients with Parkinson's disease: a preliminary study.

Authors:  Roberto Cano-de-la-Cuerda; Lydia Vela-Desojo; Juan Carlos Miangolarra-Page; Yolanda Macías-Macías; Elena Muñoz-Hellín
Journal:  Qual Life Res       Date:  2010-12-14       Impact factor: 4.147

8.  Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes.

Authors:  Frances M Weaver; Kenneth A Follett; Matthew Stern; Ping Luo; Crystal L Harris; Kwan Hur; William J Marks; Johannes Rothlind; Oren Sagher; Claudia Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff M Bronstein; Gatana Stoner; Philip A Starr; Richard Simpson; Gordon Baltuch; Antonio De Salles; Grant D Huang; Domenic J Reda
Journal:  Neurology       Date:  2012-06-20       Impact factor: 9.910

Review 9.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 10.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.